Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice

Annals of the Rheumatic Diseases

Volumn 74, Issue 12, 2015, Pages 2199-2206

  Knight, Jason S ^a   Subramanian, Venkataraman ^b   O'Dell, Alexander A ^a   Yalavarthi, Srilakshmi ^a   Zhao, Wenpu ^c   Smith, Carolyne K ^c   Hodgin, Jeffrey B ^a   Thompson, Paul R ^b   Kaplan, Mariana J ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDINE; AUTOANTIBODY; BB CL AMIDINE; CL AMIDINE; INTERFERON; PEPTIDYLARGININE DEIMINASE 4; PROTEIN ARGININE DEIMINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; UNCLASSIFIED DRUG; HYDROLASE; PROTEIN-ARGININE DEIMINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DOWN REGULATION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR TRAP; GENE EXPRESSION REGULATION; GENE MUTATION; IMMUNE COMPLEX DEPOSITION; IMMUNE COMPLEX NEPHRITIS; MOUSE; NEUTROPHIL; NONHUMAN; NOX2 GENE; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; SIGNAL TRANSDUCTION; SKIN DISEASE; SKIN PROTECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; VASCULAR DISEASES;

AMIDINES; ANIMALS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR TRAPS; HYDROLASES; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED MRL LPR; VASCULAR DISEASES;

EID: 84949904309     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205365     Document Type: Article

References (53)

1. Elkon KB, Wiedeman A. Type I IFN system in the development and manifestations of SLE. Curr Opin Rheumatol 2012;24:499-505.
2. Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011;3:73ra20.
3. Lande R, Ganguly D, Facchinetti V, et al. Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNA-Peptide Complexes in Systemic Lupus Erythematosus. Sci Transl Med 2011;3:73ra19.
4. Villanueva E, Yalavarthi S, Berthier CC, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011;187:538-52.
5. Hakkim A, Furnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA 2010;107:9813-18.
6. Leffler J, Martin M, Gullstrand B, et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol 2012;188:3522-31.
7. Leffler J, Gullstrand B, Jonsen A, et al. Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus. Arthritis Res Ther 2013;15:R84.
8. Van Avondt K, Fritsch-Stork R, Derksen RH, et al. Ligation of signal inhibitory receptor on leukocytes-1 suppresses the release of neutrophil extracellular traps in systemic lupus erythematosus. PloS one 2013;8:e78459.
9. Kahlenberg JM, Carmona-Rivera C, Smith CK, et al. Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J Immunol 2013;190:1217-26.
10. Campbell AM, Kashgarian M, Shlomchik MJ. NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus. Sci Transl Med 2012;4:157ra141.
11. Knight JS, Zhao W, Luo W, et al. Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J Clin Invest 2013;123:2981-93.
12. Li P, Li M, Lindberg MR, et al. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med 2010;207:1853-62.
13. Hemmers S, Teijaro JR, Arandjelovic S, et al. PAD4-mediated neutrophil extracellular trap formation is not required for immunity against influenza infection. PLoS One 2011;6:e22043.
14. Rohrbach AS, Slade DJ, Thompson PR, et al. Activation of PAD4 in NET formation. Front Immunol 2012;3:360.
15. Mathian A, Weinberg A, Gallegos M, et al. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black×New Zealand White) F1 but not in BALB/c mice. J Immunol 2005;174:2499-506.
16. Perry D, Sang A, Yin Y, et al. Murine models of systemic lupus erythematosus. J Biomed Biotechnol 2011;2011:271694.
17. Hron JD, Peng SL. Type I IFN protects against murine lupus. J Immunol 2004;173:2134-42.
18. Nickerson KM, Cullen JL, Kashgarian M, et al. Exacerbated autoimmunity in the absence of TLR9 in MRL.Fas(lpr) mice depends on Ifnar1. J Immunol 2013;190:3889-94.
19. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004;303:1532-5.
20. Ermert D, Urban CF, Laube B, et al. Mouse neutrophil extracellular traps in microbial infections. J Innate Immun 2009;1:181-93.
21. Manzi S, Urbach AH, McCune AB Jr., et al. Systemic lupus erythematosus in a boy with chronic granulomatous disease: case report and review of the literature. Arthritis Rheum 1991;34:101-5.
22. Cale CM, Morton L, Goldblatt D. Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology. Clin Exp Immunol 2007;148:79-84.
23. Causey CP, Thompson PR. An improved synthesis of haloaceteamidine-based inactivators of protein arginine deiminase 4 (PAD4). Tetrahedron Lett 2008;49:4383-5.
24. Bicker KL, Anguish L, Chumanevich AA, et al. D-amino acid based protein arginine deiminase inhibitors: Synthesis, pharmacokinetics, and in cellulo efficacy. ACS Med Chem Lett 2012;3:1081-5.
25. Knuckley B, Jones JE, Bachovchin DA, et al. A fluopol-ABPP HTS assay to identify PAD inhibitors. Chem Commun (Camb) 2010;46:7175-7.
26. Baranczewski P, Stanczak A, Sundberg K, et al. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep 2006;58:453-72.
27. Brothers SP, Saldanha SA, Spicer TP, et al. Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening. Mol Pharmacol 2010;77:46-57.
28. Kelley VE, Roths JB. Interaction of mutant lpr gene with background strain influences renal disease. Clin Immunol Immunopathol 1985;37:220-9.
29. Izui S, Kelley VE, Masuda K, et al. Induction of various autoantibodies by mutant gene lpr in several strains of mice. J Immunol 1984;133: 227-33.
30. Kahlenberg JM, Kaplan MJ. Little Peptide, Big Effects: The Role of LL-37 in Inflammation and Autoimmune Disease. J Immunol 2013;191:4895-901.
31. Knight JS, Kaplan MJ. Cardiovascular disease in lupus: insights and updates. Curr Opin Rheumatol 2013;25:597-605.
32. Thacker SG, Duquaine D, Park J, et al. Lupus-prone New Zealand Black/New Zealand White F1 mice display endothelial dysfunction and abnormal phenotype and function of endothelial progenitor cells. Lupus 2010;19:288-99.
33. Li P, Yao H, Zhang Z, et al. Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol Cell Biol 2008;28:4745-58.
34. Chumanevich AA, Causey CP, Knuckley BA, et al. Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor. Am J Physiol Gastrointest Liver Physiol 2011;300:G929-938.
35. Andrews BS, Eisenberg RA, Theofilopoulos AN, et al. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 1978;148:1198-215.
36. Kaplan MJ, Salmon JE. How does interferon-alpha insult the vasculature? Let me count the ways. Arthritis Rheum 2011;63:334-6.
37. Furukawa F, Tanaka H, Sekita K, et al. Dermatopathological studies on skin lesions of MRL mice. Arch Dermatol Res 1984;276:186-94.
38. Choi JY, Gao W, Odegard J, et al. Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog. Arthritis Rheum 2006; 54:3277-83.
39. Knight JS, Luo W, O'Dell AA, et al. Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ Res 2014;114:947-56.
40. Willis VC, Gizinski AM, Banda NK, et al. N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol 2011;186:4396-404.
41. Tan EM, Schur PH, Carr RI, et al. Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest 1966;45:1732-40.
42. Ho A, Magder LS, Barr SG, et al. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2342-9.
43. Mevorach D, Zhou JL, Song X, et al. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998;188:387-92.
44. Aebi M, Fah J, Hurt N, et al. cDNA structures and regulation of two interferon-induced human Mx proteins. Mol Cell Biol 1989;9:5062-72.
45. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991;9:243-69.
46. Braunstein I, Klein R, Okawa J, et al. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. Br J Dermatol 2012;166:971-5.
47. Reefman E, Kuiper H, Limburg PC, et al. Type I interferons are involved in the development of ultraviolet B-induced inflammatory skin lesions in systemic lupus erythaematosus patients. Ann Rheum Dis 2008;67:11-18.
48. Guiducci C, Tripodo C, Gong M, et al. Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J Exp Med 2010;207:2931-42.
49. Schappi MG, Jaquet V, Belli DC, et al. Hyperinflammation in chronic granulomatous disease and anti-inflammatory role of the phagocyte NADPH oxidase. Semin Immunopathol 2008;30:255-71.
50. Rieber N, Hector A, Kuijpers T, et al. Current concepts of hyperinflammation in chronic granulomatous disease. Clin Dev Immunol 2012;2012:252460.
51. Meissner F, Seger RA, Moshous D, et al. Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood 2010;116:1570-3.
52. Gardiner GJ, Deffit SN, McLetchie S, et al. A Role for NADPH Oxidase in Antigen Presentation. Front Immunol 2013;4:295.
53. Kahlenberg JM, Yalavarthi S, Zhao W, et al. An essential role for caspase-1 in the induction of murine lupus and its associated vascular damage. Arthritis Rheum 2013;66:152-62.